- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: May 2025
- Public Summary Document (PSD) May 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) May 2025 PBAC Meeting - (Word)
Repotrectinib – May 2025
Repotrectinib: Capsule 40 mg, Capsule 160 mg; Augtyro™
Last updated
9 May 2025